Navigation Links
Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
Date:2/26/2013

SAN DIEGO, Feb. 26, 2013 /PRNewswire/ -- Althea Technologies, Inc., a leading provider of biopharmaceutical development and manufacturing services, and Profectus BioSciences Inc, a technology based vaccine company, today announced the signing of a manufacturing supply agreement for plasmid DNA production. Under the agreement, Althea will provide gram-scale quantities of cGMP (current Good Manufacturing Practice) manufactured plasmid DNA expressing IL-12 to assist Profectus Biosciences' ongoing DNA vaccine development efforts, which are supported by a contract from the National Institutes of Health. IL-12 helps prompt an immune response once the DNA enters a cell, which is part of Profectus Biosciences' technology platform designed to overcome the poor delivery and immunogenicity of many DNA vaccines.

(Logo: http://photos.prnewswire.com/prnh/20121024/LA98976LOGO)

"Profectus is very pleased to establish this partnership with Althea for the production of the clinical grade plasmids for our DNA vaccine programs," said John Eldridge , Chief Scientific Officer of Profectus BioSciences. "Althea provides an unmatched combination of state-of-the-art facilities and expertise in this area and we anticipate a long and productive association." 

"We are delighted to be awarded this contract, this project has tremendous potential for treating some of the world's most devastating and challenging diseases" stated Rick Hancock , President and CEO of Althea Technologies. "By establishing this partnership, Althea will be able to leverage our plasmid manufacturing expertise to help advance this DNA vaccines program through the clinic and to the patients who need it."

About Althea Technologies, Inc.
Althea Technologies is a fully integrated, contract development and manufacturing organization located in San Diego, CA providing clinical and commercial product development services. Althea offers cGMP drug product filling in both vials and syringes, and production of microbial-derived recombinant proteins and plasmid DNA. In conjunction with these manufacturing operations, Althea offers comprehensive development services including: upstream and downstream process development, analytical development, lyophilization cycle, complex formulation, product release and ICH-compliant stability testing. Althea's formulation technology platform includes Crystalomics®, a proprietary technology that offers a formulation solution for large molecule products that must be delivered at high concentrations or as sustained release formulations. For more information, visit www.altheatech.com

About Profectus Biosciences.
Profectus BioSciences, Inc. is a technology based vaccine company devoted to the treatment and prevention of infectious diseases and related cancers, with the goal of reducing morbidity and mortality. Since its inception in 2003, the Company's strategic intent has been to acquire and develop the technologies needed to achieve this goal. The Company has licensed a group of vaccine?based technologies from Wyeth Vaccines (now Pfizer, Inc.) that greatly enhance the immunogenicity of prophylactic and therapeutic vaccines based on a "prime?boost" strategy. This strategy uses the delivery of a best?in?class pDNA vaccine to "prime" the immune system, followed by a first-in-class "boost" with an rVSV vector. Current disease and virus targets include hepatitis C virus (HCV), human papilloma virus (HPV), herpes simplex virus type 2 (HSV?2), human immunodeficiency virus (HIV), Ebola virus, Marburg Virus, the arenaviruses and malaria. The Profectus HIV DNA vaccine program has been supported through the award of a $32 M HIV Vaccine Design and Development Teams (HVDDT) contract (HHSN272200800062C) from the NIH that has supported 60% of the research, development, and manufacturing costs of the multi-antigen HIV vaccine and GENEVAX™ IL-12 programs, while the remainder of the cost has been provided through a contribution-in-kind. Partners and collaborators include Ichor Medical Systems, the Galveston National Laboratory, Yale University, the Institute of Human Virology, the Center for HIV/AIDS Vaccine Immunology, the National Cancer Institute, the NIH Division of AIDS, the Bill and Melinda Gates Foundation, the International AIDS Vaccine Initiative, the PATH Malaria Vaccine Initiative, the HIV Vaccines Trials Network, and the AIDS Clinical Trials Group. More information is available at www.ProfectusBioSciences.com.


'/>"/>
SOURCE Althea Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. University of Colorado and Orphan Technologies sign agreement
2. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
3. LaserLock Technologies Files for Provisional Patent Enabling Mobile Phones with Anti-Counterfeiting Technology
4. Going negative: Stanford scientists explore new technologies that remove atmospheric CO2
5. New modeling approach transforms imaging technologies
6. Life Technologies ayudará a identificar 20.000 restos humanos encontrados en fosas comunes en Libia
7. New supercomputer coming to EMSL this summer, supplied by Atipa Technologies
8. UT Dallas researchers awarded $4.3 million to create next-generation technologies
9. ASU partners with Life Technologies on US DHHS funded project to rapidly assess radiation dose
10. Lyncean Technologies Inc. sells Compact Light Source to Munich biomedical-imaging research center
11. NREL researchers use imaging technologies to solve puzzle of plant architecture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based and Touchless), ... published by MarketsandMarkets, the market is expected to be worth USD 18.98 billion ... Continue Reading ... ...      (Logo: ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 11, 2017 , ... At its national board meeting in ... Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space Technology ... in ARCS Alumni Hall of Fame . ASTER Labs is a technology ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/10/2017)... ... , ... San Diego-based team building and cooking events company, Lajollacooks4u, has unveiled ... bold new look is part of a transformation to increase awareness, appeal to new ... , It will also expand its service offering from its signature gourmet cooking classes ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced the ... NIH to develop RealSeq®-SC (Single Cell), expected to be ... small RNAs (including microRNAs) from single cells using NGS ... the need to accelerate development of approaches to analyze ... "New techniques for measuring levels of mRNAs ...
Breaking Biology Technology: